Depomed Reports Second Quarter 2016 Financial Results

Go back to Depomed Reports Second Quarter 2016 Financial Results

DepoMed (DEPO) PT Bumped to $19 at Piper Jaffray, Remains Sidelined

August 4, 2016 7:29 AM EDT

Piper Jaffray analyst David Amsellem bumped his price target on DepoMed Inc (NASDAQ: DEPO) to $19.00 (from $18.00) but maintained a Neutral rating.

Amsellem commented, "Depomed reported 2Q16 diluted EPS of $0.27 on revenue of $117M, compared to Street estimates of $0.25 and $118M, respectively. Notably, DEPO... More

Depomed (DEPO) Tops Q2 EPS by 2c

August 3, 2016 4:02 PM EDT

Depomed (NASDAQ: DEPO) reported Q2 EPS of $0.27, $0.02 better than the analyst estimate of $0.25. Revenue for the quarter came in at $116.7 million versus the consensus estimate of $118.2 million.

For earnings history and earnings-related data on Depomed (DEPO) click here.

... More